Previous Close | 288.69 |
Open | 290.95 |
Bid | 115.22 x 800 |
Ask | 399.00 x 1000 |
Day's Range | 281.30 - 292.66 |
52 Week Range | 256.77 - 428.36 |
Volume | |
Avg. Volume | 369,032 |
Market Cap | 13.459B |
Beta (5Y Monthly) | 1.05 |
PE Ratio (TTM) | 31.42 |
EPS (TTM) | 9.14 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | 1.36 (0.49%) |
Ex-Dividend Date | May 13, 2022 |
1y Target Est | 359.10 |
Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF. It positions Teleflex to execute its capital allocation strategy more meaningfully in the future. TFX has low leverage and enough firepower to execute on ~$2 billion in M&A. The analysts expect a disciplined approach to accretive M&A that will accrue to the
WAYNE, Pa., May 20, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices, will provide an update on its business and address its 2023-2025 business growth strategy and financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event presentations will begin at 10:00 a.m. ET and the accompanying presentation materials will be available at that time on the Company’s web site at teleflex.com. “Teleflex is
Will expand patient access to BPH treatmentWAYNE, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has received National Medical Products Administration (NMPA) approval for its UroLift® System in China for treating benign prostatic hyperplasia (BPH). Treatment with the UroLift® System is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition which may cau